Dr. Gregory T. Everson, CEO and founder of HepQuant, will discuss “Simultaneous Quantification of Native Human Liver and Porcine Liver Function in an Extracorporeal Circuit Using IV 13C-Cholate.” at the upcoming DDW 2025 Late-Breaking Plenary session on May 3, 2025. Please join him in Room 25 from 2:00 to 3:00 pm at the San Diego Convention Center.
In addition, other DDW 2025 poster presentations include:
- POSTER OF DISTINCTION – Statins and Metformin may preserve hepatic function and reduce portal-systemic shunting in advanced chronic liver disease: result with the HepQuant DuO test from the SHUNT-V study and
- Quantifying the individual impact of cardiac and liver disease on liver function and portal-systemic shunting in Fontan-associated liver disease by a simplified cholate shunt test.
Both poster presentations will occur on May 5 from 12:30 to 1:30 pm.